COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
  Global AdoptionAdoption
  Submit FeedbackFeedback [0.03-1.47]death1/14113/377Improvement, RR [CI]TreatmentControlThomas (RCT)12%0.88 [0.39-1.99]recov. time5850Asimi97%0.03 [0.00-0.44]ventilation0/2709/86CT​2Tau​2 = 1.92; I​2 = 69.7%Early treatment76%0.24 [0.04-1.63]1/46922/51376% improvementCarlucci38%0.62 [0.45-0.86]death/HPC411521Improvement, RR [CI]TreatmentControlKrishnan18%0.82 [0.62-1.09]death31/5861/94Yao34%0.66 [0.41-1.07]death73/19621/46Frontera37%0.63 [0.44-0.91]death121/1,006424/2,467Abd-Elsalam (RCT)1%0.99 [0.30-3.31]death5/965/95Al Sulaiman35%0.65 [0.41-1.01]death35/13045/129Tau​2 = 0.00; I​2 = 0.0%Late treatment33%0.67 [0.59-0.76]265/1,897556/3,35233% improvementIsrael100%0.00 [0.00-0.93]hosp.0/106,953/20,849CT​2Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP100%0.00 [0.00-0.93]0/106,953/20,849100% improvementSeet (CLUS. RCT)50%0.50 [0.34-0.75]severe case33/63464/619OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP50%0.50 [0.34-0.75]33/63464/61950% improvementYasui92%0.07 [0.01-0.54]ventilation1/206/9Improvement, RR [CI]TreatmentControlJothimani90%0.10 [0.01-1.76]death0/205/27Berrocal45%0.55 [0.23-1.31]death5/3126/89Tau​2 = 0.88; I​2 = 51.6%Sufficiency78%0.22 [0.05-0.96]6/7137/12578% improvementAll studies47%0.53 [0.39-0.72]305/3,0817,632/25,45847% improvement14 zinc COVID-19 7/30/211 OT: comparison with other treatment2 CT: study uses combined treatmentTau​2 = 0.18; I​2 = 76.2%; Z = 3.98 (p < 0.0001)Effect extraction pre-specifiedLower RiskIncreased Risk
Restrict:    All    Early    Late    Levels
PrEP Israel et al., Epidemiology and Global Health Microbiology and Infectious Disease, doi:10.7554/eLife.68165 (Peer Reviewed) hosp., ↓>99.9%, p=0.04 Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population
Details   Case control study examining medication usage with a healthcare database in Israel, showing lower risk of hospitalization with calcium + zinc supplements (defined as being picked up within 35 days prior to PCR+), however only 10 patients ..
In Vitro Panchariya et al., bioRxiv, doi:10.1101/2021.06.15.448551 (Preprint) (In Vitro) in vitro Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro
Details   In Silico and In Vitro study showing that ionic zinc inhibits SARS-CoV-2 main protease (Mpro) and inhibits viral replication. Zinc acetate inhibited viral replication in Vero E6 cells, while zinc glycinate and zinc gluconate did not at n..
Levels Verschelden et al., medRxiv, doi:10.1101/2021.06.09.21258271 (Preprint) Plasma zinc status and hyperinflammatory syndrome in hospitalized COVID-19 patients: an observational study
Details   Prospective study of 139 hospitalized COVID-19 patients, showing 96% had zinc deficiency. Higher zinc levels were associated with a shorter length of hospitalization. Mortality and ventilation was lower with higher zinc levels, but not re..
Late Al Sulaiman et al., Research Square, doi:10.21203/ (Preprint) death, ↓35.0%, p=0.05 Evaluation of Zinc Sulfate as an Adjunctive Therapy in COVID-19 Critically Ill Patients: a Two Center Propensity-score Matched Study
Details   Retrospective 266 ICU patients showing lower mortality with zinc treatment (very close to statistical significance), and higher odds of acute kidney injury.
Early Asimi et al., Endocrine Abstracts, doi:10.1530/endoabs.73.PEP14.2 (Preprint) ventilation, ↓97.4%, p<0.0001 Selenium, zinc, and vitamin D supplementation affect the clinical course of COVID-19 infection in Hashimoto’s thyroiditis
Details   Retrospective 356 Hashimoto's thyroiditis outpatients, 270 taking vitamin D, zinc, and selenium, showing significantly lower hospitalization with treatment. Authors adjust for age, gender, BMI, and smoking status, reporting statistically ..
Levels Skalny et al., Metabolites, doi:10.3390/metabo11040244 (Peer Reviewed) Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers
Details   Analysis of serum metal levels in 150 COVID-19 patients and 44 controls, finding that COVID-19 severity was associated with lower serum Ca, Fe, Se, Zn levels when compared to controls.
PEP Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed) severe case, ↓49.7%, p=0.03 Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
Details   Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin ..
Levels Dubourg et al., Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2021.01.012 (Peer Reviewed) Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with Zinc COVID-19 patients?
Details   Retrospective 275 patients showing zinc levels significantly lower in patients with poor outcomes, 840 vs. 970 µg/L, p< 0.0001.
Early Thomas et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2021.0369 (Peer Reviewed) recov. time, ↓11.9%, p=0.38 Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial
Details   Small 214 low-risk outpatient RCT showing non-statistically significant faster recovery with zinc and with vitamin C. The zinc dosage appears low, 50mg zinc glcuonate (7mg elemental zinc). Study performed in the USA where zinc deficiency ..
Review Joachimiak et al., PLOS Neglected Tropical Diseases, doi:10.1371/journal.pntd.0008895 (Review) (Peer Reviewed) review Zinc against COVID-19? Symptom surveillance and deficiency risk groups
Details   Literature review concluding that zinc should be included as part of preventative supplementation for COVID-19, in general for support of immune health, and should also be considered in the context of zinc deficiency acquired during a vir..
Review McCullough et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.264 (Review) (Peer Reviewed) review Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)
Details   Review urging early treatment of COVID-19 with sequential multidrug treatment that has been shown to be safe and effective. Proposed treatment includes zinc, vitamin D & C, quercetin, and depending on age, comorbidities, and symptoms may ..
Late Abd-Elsalam et al., Biological Trace Element Research, doi:10.1007/s12011-020-02512-1 (Peer Reviewed) death, ↓1.0%, p=0.99 Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial
Details   191 patient RCT in Egypt comparing the addition of zinc to HCQ, not showing a significant difference. Clinical recovery at 28 days was 79.2% in the zinc group and 77.9% control, p = 0.969. Mechanical ventilation was used with 4 patients..
In Silico Pormohammad et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2020.4790 (Peer Reviewed) Zinc and SARS‑CoV‑2: A molecular modeling study of Zn interactions with RNA‑dependent RNA‑polymerase and 3C‑like proteinase enzymes
Details   In Silico analysis supporting the hypothesis that Zn would bind and regulate the enzymatic activities of 3CLpro and RdRp of SARS‑CoV-2 and therefore inhibit viral replication. Since Zn has established immune health benefits, is readily av..
Late Frontera et al., Research Square, doi:10.21203/ (Preprint) death, ↓37.0%, p=0.01 Treatment with Zinc is Associated with Reduced In-Hospital Mortality Among COVID-19 Patients: A Multi-Center Cohort Study
Details   Retrospective 3,473 hospitalized patients showing 37% lower mortality with HCQ+zinc. PSM aHR 0.63, p=0.015 regression aHR 0.76, p = 0.023
Levels Berrocal et al., Research Square, doi:10.21203/ (Preprint) death, ↓44.8%, p=0.23 Zinc and Vitamin A Deficiency Predisposes to the Need for Intubation and ICU Admission in Patients With COVID-19. An Observational Study
Details   Retrospective 120 hospitalized patients showing zinc deficiency associated with a higher ICU admission rate (61.8% vs.29%; p = 0.002) and a higher rate of intubation (87.5% vs. 12.5%; p = 0.002).
Early Derwand et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106214 (preprint 7/3) (Peer Reviewed) death, ↓79.4%, p=0.12 COVID-19 Outpatients – Early Risk-Stratified Treatment with Zinc Plus Low Dose Hydroxychloroquine and Azithromycin: A Retrospective Case Series Study
Details   79% lower mortality and 82% lower hospitalization with early HCQ+AZ+Z. Retrospective 518 patients (141 treated, 377 control).
PrEP Heller et al., Redox Biology, doi:10.1016/j.redox.2020.101764 (Peer Reviewed) Prediction of Survival Odds in COVID-19 by Zinc, Age and Selenoprotein P as Composite Biomarker
Details   Analysis of 35 COVID-19 patients showing a significant correlation for serum zinc levels between COVID-19 patients and controls, and between COVID-19 survivors and non-survivors.
Late Vogel-González et al., medRxiv, doi:10.1101/2020.10.07.20208645 (Preprint) Low zinc levels at clinical admission associates with poor outcomes in COVID-19
Details   Shows a correlation between serum zinc levels and COVID-19 outcome. Almost all patients received HCQ.
Levels Jothimani (Peer Reviewed) death, ↓89.7%, p=0.06 COVID-19: Poor outcomes in patients with zinc deficiency
Details   Prospective study of zinc levels in 47 hospitalized COVID-19 patients and 45 healthy controls. COVID-19 patients had significantly lower zinc levels (74.5 vs. 105.8 median μg/dl, p < 0.001). 57.4% of COVID-19 patients were zinc deficient,..
Levels Yasui et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.09.008 (Peer Reviewed) ventilation, ↓92.5%, p=0.001 Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19
Details   Retrospective 62 hospitalized patients, 29 with serum zinc data, showing significantly lower serum zinc levels for severe COVID-19 cases (intubation) compared with mild and moderate cases, p = 0.005. Authors recommend zinc supplementation.
Late Yao et al., Chest, doi:10.1016/j.chest.2020.06.082 (Peer Reviewed) death, ↓34.0%, p=0.09 The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19
Details   Retrospective 242 hospitalized patients in the USA showing adjusted hazard ratio for zinc treatment, aHR 0.66 [0.41-1.07]. [1] notes that the study would be more informative if baseline serum zinc levels were known.
Late Krishnan et al., J Clin Anesth., doi:10.1016/j.jclinane.2020.110005 (Peer Reviewed) death, ↓17.6%, p=0.18 Clinical comorbidities, characteristics, and outcomes of mechanically ventilated patients in the State of Michigan with SARS-CoV-2 pneumonia
Details   Retrospective 152 mechanically ventilated patients in the USA showing unadjusted lower mortality with vitamin C, vitamin D, HCQ, and zinc treatment, statistically significant only for vitamin C.
Late Finzi et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.06.006 (Peer Reviewed) Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients
Details   Case report on 4 patients treated with high dose zinc. All patients experienced significant improvement after one day.
Late Carlucci et al., J. Med. Microbiol., Sep 15, 2020, doi: 10.1099/jmm.0.001250 (preprint 5/8) (Peer Reviewed) death/HPC, ↓37.8%, p=0.002 Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients
Details   Retrospective 932 patients. Addition of Zinc to HCQ+AZ reduces mortality / transfer to hospice, ICU admission, and the need for ventilation. Reduction in mortality or transfer to hospice adjusted odds ratio OR 0.56, p = 0.002; increase i..
In Vitro te Velthuis et al., PLOS Pathogens 2010, 6:11, doi:10.1371/journal.ppat.1001176 (Peer Reviewed) (In Vitro) in vitro Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture
Details   Shows that the combination of Zn2+ and a zinc ionophore (pyrithione) at low concentrations inhibits the replication of SARS-CoV and equine arteritis virus (EAV) in cell culture. Recommends further study of the use of zinc-ionophores as an..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop to submit images   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.